Gland Pharma Limited (BSE:543245) is looking for acquisition opportunities. Srinivas Sadu, Managing Director and Chief Executive Officer said, "We're also looking at acquisition opportunities to help expedite the development process. At the same time, we're also working towards charting down the road map to establish the biosimilar CDMO vertical.

Collaboration with established biosimilar players and acquisitions can help us accelerate the push in this regard. We remain optimistic on the prospects for this year and hope to continue the growth momentum for all our stakeholders".